5-甲氧基-4,4-二甲基-5-氧代戊酸 | 2840-71-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 5-甲氧基-4,4-二甲基-5-氧代戊酸
• 中文别名: 5-甲氧基-4,4-二甲基-5-氧代戊酸(别名:2,2-二甲基-戊二酸-1-甲酯)
• 英文名称: 5-methoxy-4,4-dimethyl-5-oxopentanoic acid
• 英文别名: methyl-4-carboxy-2,2-dimethylbutyrate
• CAS: 2840-71-3
• 化学式: C₈H₁₄O₄
• mdl: MFCD11553057
• 分子量: 174.197
• InChiKey: ZROBYBYCKVTNOI-UHFFFAOYSA-N

物化性质

• 熔点：
  43.5-45.0℃ (ligroine )
• 沸点：
  135-140℃ (12 Torr)
• 密度：
  1.097±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  5-甲氧基-4,4-二甲基-5-氧代戊酸 在 盐酸 、 氯化亚砜 作用下， 以 乙醚 为溶剂， 反应 19.0h， 生成 methyl 6-chloro-2,2-dimethyl-5-oxohexanoate
  参考文献：
  名称：

  Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation of L-691,816

  摘要：

  Thiopyrano[2,3,4-c,d]indoles are a new class of 5-lipoxygenase (5-LO) inhibitors. SAR studies have demonstrated that the thiopyran ring, the 5-phenylpyridine substituent, and an acidic functional group on a four-carbon C-2 side chain are all required for optimal inhibitor potency. In contrast, the indolic nitrogen may be substituted with a variety of lipophilic groups. As a result of the SAR investigation, 44 (L-691,816; 5-[3-[1-(4-chlorobenzyl)-4-methyl-6-[(5-phenylpyridin-2-yl)methoxy]-4,5-dihydro-1H-thiopyrano[2,3,4-c,d]indol-2-yl]-2,2-dimethylpropyl]-1H-tetrazole) has been identified as a potent inhibitor of the 5-LO reaction both in vitro and in a range of in vivo models. Compound 44 inhibits 5-HPETE production by both rat and human 5-LO and LTB4 synthesis in human PMN leukocytes (IC50s 16,75, and 10 nM, respectively). The mechanism of inhibition of 5-LO activity by compound 44 appears to involve the formation of a reversible deadend complex with the enzyme and does not involve reduction of the nonheme iron of 5-LO. Compound 44 is highly selective for 5-LO when compared to the inhibition of human FLAP, porcine 12-LO, and also ram seminal vesicle cyclooxygenase. In addition, 44 is orally active in a rat pleurisy model (inhibition of LTB4, ED50 = 1.9 mg/kg; 8 h pretreatment) as well as in the hyperreactive rat model of antigen-induced dyspnea (ED50 = 0.1 mg/kg;2-h pretreatment). Excellent functional activity was also observed in both the conscious allergic monkey and sheep models of asthma. In the latter case, the functional activity observed correlated with the inhibition of urinary LTE4 excretion.

  DOI：

  10.1021/jm00071a008
• 作为产物：
  描述：

  2,2-二甲基戊二酸二甲酯 在 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以99%的产率得到5-甲氧基-4,4-二甲基-5-氧代戊酸
  参考文献：
  名称：

  IRAK4靶向PROTAC的设计、合成和生物学评价

  摘要：

  白细胞介素 1 受体相关激酶 4 (IRAK4) 是由 MYD88 L265P 突变体驱动的弥漫性大 B 细胞淋巴瘤的一个有希望的治疗靶点，同时作为下游信号分子的激酶和支架蛋白。虽然以前仅用激酶抑制剂调节 IRAK4 活性的努力显示出中等疗效，但蛋白质降解可能提供一种解决方案来阻断 IRAK4 激酶活性和支架能力。为此，发现了强效的 IRAK4 降解剂9，它有效地抑制了下游 NF-κB 信号的激活，并优于母体化合物1。此外，与母体化合物相比，化合物9在降低 OCI-LY10 和 TMD8 细胞的活力方面显示出显着优势1 . 这些结果强调了消除 IRAK4 的激酶和支架功能可能比单独抑制激酶活性产生更好和更广泛的功效的潜力。

  DOI：

  10.1021/acsmedchemlett.0c00474

文献信息

• Reaction of silylketene acetals with acryloyl and mono substituted acryloyl chlorides.
  作者：Gérard Rousseau、Luis Blanco

  DOI：10.1016/s0040-4039(00)98988-3

  日期：1985.1

  The reaction of silylketene acetals with acryloyl, methacryloyl and crotonyl chlorides gave, after addition of methanol, mainly substituted glutaric esters, probably via a (2 + 2) cycloaddition.

  在添加甲醇后，甲硅烷基乙烯酮缩醛与丙烯酰基，甲基丙烯酰基和巴豆酰氯的反应可能主要是通过（2 + 2）环加成反应得到的主要是取代的戊二酸酯。
• TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF
  申请人：JAPAN TOBACCO INC.

  公开号：US20160137639A1

  公开（公告）日：2016-05-19

  A compound represented by Formula [I]: or pharmaceutically acceptable salt thereof, wherein each symbol is as defined in the description.

  由式[I]表示的化合物： 或其药学上可接受的盐，其中每个符号如描述中所定义。
• ORGANIC COMPOUNDS
  申请人：Mogi Muneto

  公开号：US20090118287A1

  公开（公告）日：2009-05-07

  The present invention provides a compound of formula (I): wherein the variants R1, R2, R3, R4, R5, R6, R7 are as defined herein, and wherein said compound is an inhibitor of CETP, and thus can be employed for the treatment of a disorder or disease mediated by CETP or responsive to the inhibition of CETP.

  本发明提供了一种化合物，其化学式为（I）：其中变体R1、R2、R3、R4、R5、R6、R7如本文所定义，并且所述化合物是CETP的抑制剂，因此可用于治疗由CETP介导或对CETP抑制响应的疾病或疾病。
• Substituted monocyclic CGRP receptor antagonists
  申请人：Wood Michael R.

  公开号：US20070265225A1

  公开（公告）日：2007-11-15

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , m, n, J, Q, R 4 , E a , E b , E c , R 6 , R 7 , R e , R f , R PG and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式I的化合物：(其中变量A1、A2、A3、A4、m、n、J、Q、R4、Ea、Eb、Ec、R6、R7、Re、Rf、RPG和Y如本文所述)是CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。
• SUR LA DOUBLE ÉNOLISATION DE LA DIMÉTHYL-3,3 CYCLOHEXANONE
  作者：J. Champagne、H. Favre、D. Vocelle、Mlle I. Zbikowski

  DOI：10.1139/v64-039

  日期：1964.2.1

  not available

  不可用